COMPARISON OF THE EFFICACY OF CLINDAMYCIN PHOSPHATE GEL 1% VERSUS ONCE-DAILY DAPSONE GEL 5% IN THE TREATMENT OF MODERATE ACNE VULGARIS AT THE TERTIARY CARE HOSPITAL, KARACHI

Main Article Content

Parisa Sanawar
Rabia Ghafoor
Nazia Jabeen
Khadija Asadullah
Misbah Qadir
Faiza Inam Siddiqui

Keywords

Acne Vulgaris, 1% Clindamycin, 5% Dapsone, Topical Therapy

Abstract

Objective: To evaluate the efficacy of clindamycin phosphate 1% gel versus Once-daily dapsone 5% gel in the treatment of moderate acne vulgaris at Tertiary Care Hospital, Karachi.


Study design: Randomized controlled trial.


Place and duration of study: This study was conducted at Department of Dermatology, Jinnah Postgraduate Medical Centre, Karachi from August 2022 till February 2023.


Material and methods: Data was prospectively collected from patients after taking consent. The sample size for the study was 100 patients, 50 in each group (A-Clindamycin and B- Dapsone) were included. Patients presenting with moderate acne vulgaris in either group were assessed for degree of improvement using Global Acne Grading Scale and patients achieving a score of ≤ 18 after 12 weeks of treatment was labeled as efficacy. Data was analyzed on SPSS Version 24.


Results: The study involved participants aged 20-70 years with Group A (mean age 24.20±5.99) and Group B (mean age 26.221±6.50). In both groups, predominantly there were females, majority in the 20- 49 age range. Efficacy was significantly higher in Group B (82%) compared to Group A (12%). Stratification by gender, and age revealed substantial differences in efficacy, particularly for participants with acne duration ≤ 3 months.


Conclusion: The outcome of this study demonstrates that dapsone 5% gel monotherapy had better efficacious results compared to the clindamycin phosphate 1% gel monotherapy after 12 weeks of treatment, with convenience of once-daily topical application.

Abstract 319 | pdf Downloads 105

References

1. Tan AU, Schlosser BJ, Paller AS. A review of diagnosis and treatment of acne in adult female patients. Int J Womens Dermatol. 2017 Dec 23;4(2):56-71.
2. Adebamowo C.A., Spiegelman D., Danby F.W., Frazier A.L., Willett W.C., Holmes M.D. High school dietary dairy intake and teenage acne. J Am Acad Dermatol. 2005;52(2):207–14.
3. Agarwal US, Besarwal RK, Bhola K. Oral isotretinoin in different dose regimens for acne vulgaris: A randomized comparative trial. Indian J Dermatol Venereol Leprol. 2011;77(6):688–94.
4. Akman A, Durusoy C, Senturk M, Koc CK, Soyturk D, Alpsoy E. Treatment of acne with intermittent and conventional isotretinoin: a randomized, controlled multicenter study. Arch Dermatol Res. 2007;299(10):467–73.
5. Zhu YI, Stiller MJ. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol. 2001;45(3):420‒434.
6. Ross CM. The treatment of acne vulgaris with dapsone. Br J Dermatol. 1961;73:367‒70.
7. Czemielewski J, Michel S, Bouclier M, et al. Adapalene biochemistry and the evolution of a new topical retinoid for treatment of acne. J Eur Acad Dermatol Venereol. 2001;15(3):5‒12.
8. Nast A, Dreno B, Bettoli V, et al. European evidence-based (s3) guidelines for the treatment of acne-update 2016 short version. J Eur Acad Dermatol Venereol. 2016;30(8):1261‒68.
9. Lynde CW, Andriessen A. Cohort study on the treatment with dapsone 5% gel of mild to moderate inflammatory acne of the face in women. Skinmed. 2014;12(1):15‒21.
10. Taghetti E, Harper JC, Oefelein MG. The efficacy and tolerability of dapsone 5% gel in female Vs males patients with facial and vulgaris, gender as a clinically relevant outcome variable. J Drug Dermatol. 2012;11(12):1417‒21.
11. Brar BK, Kumar S, Sethi N. Comparative evaluation of dapsone 5% gel vs. clindamycin 1% gel in mild to moderate acne vulgaris. Gulf J Dermatol Venereol. 2016;23(1):34-9.
12. Adityan B, Kumari R, Thappa DM. Scoring systems in acne vulgaris. J Dermatol Venereol Leprol 2009;75:323.
13. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: A systematic analysis for the global burden of disease study 2010. Lancet 2012;380:2163-96.
14. Tan AU, Schlosser BJ, Paller AS. A review of diagnosis and treatment of acne in adult female patients. Int J Womens Dermatol 2018;4:56-71.
15. Katsambas A, Towarky AA, Stratigos J. Topical clindamycin phosphate compared with oral tetracycline in the treatment of acne vulgaris. Br J Dermatol 1987;116:387-91.
16. Shalita AR, Smith EB, Bauer E. Topical erythromycin v clindamycin therapy for acne: A multicenter, double-blind comparison. Arch Dermatol 1984;120:351-5.
17. Chu A, Huber FJ, Plott RT. The comparative efficacy of benzoyl peroxide 5%/erythromycin 3% gel and erythromycin 4%/zinc 1.2% solution in the treatment of acne vulgaris. Br J Dermatol 1997;136:235-8.
18. Drucker CR. Update on topical antibiotics in dermatology. Dermatol Ther 2012;25:6‐11.
19. Worret WI, Fluhr JW. Topische Therapie mit Benzoylperoxid, Antibiotika und Azelainsäurebei der Akne (Acne therapy with topical benzoyl peroxide, antibiotics and azelaic acid). J Dtsch Dermatol Ges 2006;4:293‐300.
20. Patel M, Bowe WP, Heughebaert C, Shalita AR. The development of antimicrobial resistance due to the antibiotic treatment of acne vulgaris: A review. J Drugs Dermatol 2010;9:655‐64.
21. Guin JD, Reynolds R, Gielerak PL. Penetration of topical clindamycin into comedones. J Am Acad Dermatol 1980;3:153-6.
22. Tan J. Dapsone 5% gel: A new option in topical therapy for acne. Skin Ther Lett 2012;17:1-3.
23. Verma R, Yadav P, Chudhari M, Patel J, Umrigar D. Comparison of efficacy of two topical drug therapy of acne vulgaris–1% clindamycin versus 5% dapsone: A split face comparative study. National Journal of Physiology, Pharmacy and Pharmacology. 2022;12(6):817-22.

Most read articles by the same author(s)